Gyon Technologies Capital Management’s Cytokinetics CYTK Stock Holding History

Gyon Technologies Capital Management’s Portfolio CYTK Stock Details CYTK Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2022 Q4	–	Sell	-5,064	Closed	-$245K	–	508
2022 Q3	$245K	Sell	5,064 -15,038	-75%	-$724K	0.08%	305
2022 Q2	$790K	Buy	+20,102	New	+$809K	0.22%	130
2022 Q1	–	Sell	-13,378	Closed	-$610K	–	341
2021 Q4	$610K	Sell	13,378 -44,370	-77%	-$1.71M	0.11%	254
2021 Q3	$2.06M	Buy	57,748 +6,764	+13%	+$199K	0.56%	54
2021 Q2	$1.01M	Buy	+50,984	New	+$1.2M	0.33%	101

Other funds holding CYTK

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Lord, Abbett & Co Jersey City, New Jersey $30.6B AUM 57.44% 1-Year Est. Return

PCH

Polar Capital Holdings London, United Kingdom $28.2B AUM 115.26% 1-Year Est. Return

RTW Investments New York $10B AUM 135.35% 1-Year Est. Return

PHS

PFM Health Sciences San Francisco, California $1.1B AUM 57.92% 1-Year Est. Return

PAMS

Pictet Asset Management (Switzerland) Geneva 73, Switzerland $84.3B AUM 26.5% 1-Year Est. Return

Gyon Technologies Capital Management's CYTK Position: Q4 2022 in Review

Gyon Technologies Capital Management sold out of Cytokinetics (CYTK) in Q4 2022, closing a stake of 5,064 shares — an estimated $245K sold.

Gyon Technologies Capital Management first reported a position in CYTK in Q2 2021 and held it in 5 quarters. The position peaked at $2.06M in Q3 2021. 277 funds tracked by Wall St. Rank hold CYTK as of Q4 2022.

Gyon Technologies Capital Management reported no remaining Cytokinetics position as of Q4 2022 after selling out during the quarter.
Gyon Technologies Capital Management sold 5,064 Cytokinetics shares in Q4 2022, an estimated $245K.
Gyon Technologies Capital Management first reported a position in Cytokinetics in Q2 2021 and held it in 5 quarters.
Gyon Technologies Capital Management's Cytokinetics position peaked at $2.06M in Q3 2021.
277 funds tracked by Wall St. Rank held Cytokinetics as of Q4 2022.

Based on Gyon Technologies Capital Management's 13F filing for Q4 2022, filed 13 Feb 2023.